The radioimmunoconjugate 131 I-tositumomab has shown promise in the treatment of recurrent follicular lymphoma. For the first time, Kaminski et al. have used the drug in previously untreated ...

supporting the potential of 177Lu-RAD204 for a tumor-agnostic indication and as an effective radioimmunotherapy based on a pan-tumor predictive biomarker. “With RAD204, we hope to provide an ...

My research focuses on the development of a theranostic platform approach for pretargeted radioimmunotherapy (PRIT) of solid human tumors. We call this strategy “DOTA-PRIT,” which is short for “DOTA ...

About Y-mAbs Y-mAbs is a commercial-stage biopharmaceutical company focused on the development and commercialization of novel, radioimmunotherapy and antibody-based therapeutic cancer products. The ...

(the “Company” or “Y-mAbs”) (Nasdaq: YMAB), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel radioimmunotherapy and antibody-based ...